The report will be delivered in 2-3 business days.

Drugs For Benign Prostatic hypertrophy Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Starting Price : $5000 | Pages : 175 | Published : January 2021 | SKU CODE : 7222 | Format :


The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

The global drugs for benign prostatic hypertrophy market is expected to grow from $4.15 billion in 2020 to $4.79 billion in 2021 at a compound annual growth rate (CAGR) of 15.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.3 billion in 2025 at a CAGR of 7.1%.

The rising male geriatric population globally is driving the market for benign prostatic hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health(NIH), benign prostatic hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of benign prostatic hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume benign prostatic hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat benign prostatic hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA).

Combination drugs are increasingly being used in the treatment of benign prostatic hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of benign prostatic hypertrophy.

Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale.

Major players in the market are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC.

The global drugs for benign prostatic hypertrophy market is segmented -

1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others

2) By End User: Hospital Pharmacies, Retail Pharmacies, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    1. Executive Summary

    2. Drugs For Benign Prostatic hypertrophy Market Characteristics

    3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

    4. Impact Of COVID-19 On Drugs For Benign Prostatic hypertrophy

    5. Drugs For Benign Prostatic hypertrophy Market Size And Growth

    5.1. Global Drugs For Benign Prostatic hypertrophy Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Drugs For Benign Prostatic hypertrophy Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Drugs For Benign Prostatic hypertrophy Market Segmentation

    6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Alpha Blocker

     5-alpha Reductase Inhibitor

    Phosphodiesterase-5 Inhibitor

    Others

    6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Others

    6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

    7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market  

    8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Drugs For Benign Prostatic hypertrophy Market  

    9.1. China Drugs For Benign Prostatic hypertrophy Market Overview  

    9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Drugs For Benign Prostatic hypertrophy Market  

    10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Drugs For Benign Prostatic hypertrophy Market  

    11.1. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Drugs For Benign Prostatic hypertrophy Market  

    12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Drugs For Benign Prostatic hypertrophy Market  

    13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Drugs For Benign Prostatic hypertrophy Market  

    14.1. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Drugs For Benign Prostatic hypertrophy Market  

    15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview

    15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Drugs For Benign Prostatic hypertrophy Market  

    16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Drugs For Benign Prostatic hypertrophy Market  

    17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Drugs For Benign Prostatic hypertrophy Market  

    18.4. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.5. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Drugs For Benign Prostatic hypertrophy Market  

    19.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview

    19.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Drugs For Benign Prostatic hypertrophy Market  

    20.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Drugs For Benign Prostatic hypertrophy Market  

    21.1. North America Drugs For Benign Prostatic hypertrophy Market Overview

    21.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Drugs For Benign Prostatic hypertrophy Market  

    22.1. USA Drugs For Benign Prostatic hypertrophy Market Overview

    22.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Drugs For Benign Prostatic hypertrophy Market  

    23.1. South America Drugs For Benign Prostatic hypertrophy Market Overview

    23.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Drugs For Benign Prostatic hypertrophy Market  

    24.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Drugs For Benign Prostatic hypertrophy Market  

    25.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview

    25.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Drugs For Benign Prostatic hypertrophy Market  

    26.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview

    26.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

    27.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape

    27.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles

    27.2.1. Allergan PLC

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2.  Astellas Pharma Inc.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3.  Boehringer Ingelheim

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4.  Eli Lilly and Company

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5.  GlaxoSmithKline PLC

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Drugs For Benign Prostatic hypertrophy Pipeline Analysis

    29. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

    30. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 27: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 28: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 29: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 31: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 32: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 33: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 34: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 35: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 36: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 37: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 38: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 39: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 40: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 41: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 42: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 43: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 44: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 45: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 46: Allergan PLC Financial Performance
  • Table 47:  Astellas Pharma Inc. Financial Performance
  • Table 48:  Boehringer Ingelheim Financial Performance
  • Table 49:  Eli Lilly and Company Financial Performance
  • Table 50:  GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation  By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 27: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 28: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 29: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 31: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 32: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 33: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 34: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 35: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 36: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 37: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 38: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 39: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 40: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 41: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 42: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 43: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 44: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 45: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 46: Allergan PLC Financial Performance
  • Figure 47:  Astellas Pharma Inc. Financial Performance
  • Figure 48:  Boehringer Ingelheim Financial Performance
  • Figure 49:  Eli Lilly and Company Financial Performance
  • Figure 50:  GlaxoSmithKline PLC Financial Performance
Global Cancer Monoclonal Antibodies Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Clinical Nutrition Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cervical Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Central Nervous System Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Checkpoint Inhibitors Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Culture Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell And Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report
Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Musculoskeletal Drugs Market Global Briefing 2018
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)